A phase III study of STI571 versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in patients with newly diagnosed, previously untreated, Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).

Trial Profile

A phase III study of STI571 versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in patients with newly diagnosed, previously untreated, Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Imatinib (Primary) ; Cytarabine; Interferon alpha
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms IRIS
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Mar 2017 11 year follow up results assessing long term safety and efficacy published in the New England Journal of Medicine.
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register DRKS00003841).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top